Los Angeles Capital Management LLC Has $240,000 Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Los Angeles Capital Management LLC trimmed its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 56.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,846 shares of the biotechnology company’s stock after selling 48,497 shares during the period. Los Angeles Capital Management LLC’s holdings in Ironwood Pharmaceuticals were worth $240,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IRWD. CWM LLC increased its holdings in Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 2,345 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Ironwood Pharmaceuticals by 152.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 2,645 shares in the last quarter. GAMMA Investing LLC increased its holdings in Ironwood Pharmaceuticals by 344.1% during the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 8,156 shares in the last quarter. First Dallas Securities Inc. acquired a new stake in Ironwood Pharmaceuticals during the 2nd quarter valued at $73,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter valued at $91,000.

Ironwood Pharmaceuticals Stock Up 0.9 %

NASDAQ:IRWD opened at $4.57 on Monday. Ironwood Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $15.70. The firm has a market capitalization of $730.01 million, a P/E ratio of -0.67 and a beta of 0.49. The stock’s fifty day simple moving average is $5.55 and its 200-day simple moving average is $6.77.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Wells Fargo & Company lowered their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, August 9th. Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price for the company. Capital One Financial cut Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $12.00 to $4.00 in a research note on Thursday, August 8th. Craig Hallum lowered their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 16th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $13.57.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the transaction, the insider now directly owns 284,661 shares in the company, valued at $1,215,502.47. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 12.90% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.